Advances in the Systemic Treatment of Metastatic Melanoma (CancerNetwork)

This topic is empty.

Post

- May 16, 2013 at 10:37 pm
- Quote
Gene_S
Participant
Advances in the Systemic Treatment of Metastatic Melanoma
Melinda Yushak, Harriet M. Kluger, Mario Sznol
Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.

The Article Reviewed:
• Treatment for Advanced Melanoma: New Drugs, New Opportunities, New Challenges
• The Past, Present, and Future of Melanoma Therapy

To view this email as a web page, click here.

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Advances in the Systemic Treatment of Metastatic Melanoma (CancerNetwork)

About the MRF Patient Forum

Popular Topics

Advances in the Systemic Treatment of Metastatic Melanoma (CancerNetwork)

About the MRF Patient Forum

Popular Topics

Topic Tags